Cargando…

Medical Therapy of Acromegaly

This paper outlines the present status of medical therapy of acromegaly. Indications for permanent postoperative treatment, postirradiation treamtent to bridge the interval until remission as well as primary medical therapy are elaborated. Therapeutic efficacy of the different available drugs—somato...

Descripción completa

Detalles Bibliográficos
Autor principal: Plöckinger, U.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3328958/
https://www.ncbi.nlm.nih.gov/pubmed/22550484
http://dx.doi.org/10.1155/2012/268957
_version_ 1782229792967360512
author Plöckinger, U.
author_facet Plöckinger, U.
author_sort Plöckinger, U.
collection PubMed
description This paper outlines the present status of medical therapy of acromegaly. Indications for permanent postoperative treatment, postirradiation treamtent to bridge the interval until remission as well as primary medical therapy are elaborated. Therapeutic efficacy of the different available drugs—somatostatin receptor ligands (SRLs), dopamine agonists, and the GH antagonist Pegvisomant—is discussed, as are the indications for and efficacy of their respective combinations. Information on their mechanism of action, and some pharmakokinetic data are included. Special emphasis is given to the difficulties to define remission criteria of acromegaly due to technical assay problems. An algorithm for medical therapy in acromegaly is provided.
format Online
Article
Text
id pubmed-3328958
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-33289582012-05-01 Medical Therapy of Acromegaly Plöckinger, U. Int J Endocrinol Review Article This paper outlines the present status of medical therapy of acromegaly. Indications for permanent postoperative treatment, postirradiation treamtent to bridge the interval until remission as well as primary medical therapy are elaborated. Therapeutic efficacy of the different available drugs—somatostatin receptor ligands (SRLs), dopamine agonists, and the GH antagonist Pegvisomant—is discussed, as are the indications for and efficacy of their respective combinations. Information on their mechanism of action, and some pharmakokinetic data are included. Special emphasis is given to the difficulties to define remission criteria of acromegaly due to technical assay problems. An algorithm for medical therapy in acromegaly is provided. Hindawi Publishing Corporation 2012 2012-04-10 /pmc/articles/PMC3328958/ /pubmed/22550484 http://dx.doi.org/10.1155/2012/268957 Text en Copyright © 2012 U. Plöckinger. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Plöckinger, U.
Medical Therapy of Acromegaly
title Medical Therapy of Acromegaly
title_full Medical Therapy of Acromegaly
title_fullStr Medical Therapy of Acromegaly
title_full_unstemmed Medical Therapy of Acromegaly
title_short Medical Therapy of Acromegaly
title_sort medical therapy of acromegaly
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3328958/
https://www.ncbi.nlm.nih.gov/pubmed/22550484
http://dx.doi.org/10.1155/2012/268957
work_keys_str_mv AT plockingeru medicaltherapyofacromegaly